Efficacy of statins in combination with interferon therapy in multiple sclerosis: A meta-analysis

American Journal of Health-System Pharmacy

Volumn 69, Issue 17, 2012, Pages 1494-1499

  Bhardwaj, Shilpa ^a   Coleman, Craig I ^b,c   Sobieraj, Diana M ^b,c  

^a GRIFFIN HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BETA1A INTERFERON; SIMVASTATIN;

ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; EXPANDED DISABILITY STATUS SCALE; HEALTH CARE QUALITY; HUMAN; INCIDENCE; INFORMATION RETRIEVAL; JADAD SCORE; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; RECURRENCE RISK; RELAPSE; RISK FACTOR;

EID: 84865966708     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110675     Document Type: Article

References (16)

1. Kobelt G, Berg J, Atherly D et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006; 66:1696-702. (Pubitemid 43964625)
2. Goodin DS, Froham EM, Garmany GP Jr et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002; 58:169-78. [Erratum, Neurology. 2002; 59:480.] (Pubitemid 34086933)
3. Kieseier BC, Archelos JJ, Hartung HP. Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases. Arch Neurol . 2004; 61:929-32. (Pubitemid 38747335)
4. Bartosik-Psujek H, Tabarkiewicz J, Pocinska K et al. Immunomodulatory effects of IFN-beta and lovastatin on immunophenotype of monocyte-derived dendritic cells in multiple sclerosis. Arch Immunol Ther Exp. 2010; 58:313-9.
5. Baker D, Adamson P, Greenwood J. Potential of statins for the treatment of multiple sclerosis. Lancet Neurol. 2003; 2:9-10. (Pubitemid 37443335)
6. Neuhaus O, Strasser-Fuchs S, Fazekas F et al. Statins as immunomodulators: comparison with interferon-β1b in MS. Neurology. 2002; 59:990-7.
7. Sellner J, Weber MS, Vollmar P et al. The combination of interferon-beta and HMG-CoA reductase inhibition in multiple sclerosis: enthusiasm lost too soon? CNS Neurosci Ther. 2010; 16:362-73.
8. Sorensen PS, Lycke J, Erälinna JP et al. Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol. 2011; 10:691-701.
9. Togha M, Karvigh SA, Nabavi M et al. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Mult Scler. 2010; 16:848-54.
10. Lanzillo R, Orefice G, Quarantelli M et al. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler. 2010; 16:848-54.
11. Birnbaum G, Cree B, Altafullah I et al. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2008; 71:1390-5.
12. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17:1-12. (Pubitemid 26120810)
13. Follman D, Elliot P, Suh I et al. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol. 1992; 45:769-73.
14. ClinicalTrials.gov. Safety and efficacy of pravastatin in relapsing-remitting multiple sclerosis. http://clinicaltrials.gov/ ct2/show/NCT00200655 (accessed 2011 Sep 10).
15. ClinicalTrials.gov. Efficacy, safety and tolerability of atorvastatin 40 mg in patients with relapsing-remitting multiple sclerosis treated with interferon-beta- 1b. http://clinicaltrials.gov/ct2/show/ NCT01111656 (accessed 2011 Sep 10).
16. Higgins JT, Green S, eds. Cochrane handbook for systematic reviews of interventions, version 5.1.0, updated 2011 Mar. www.cochrane-handbook.org (accessed 2012 Apr 18).